Top 3 Medical Products Turned Down By Dragons | COMPILATION | Dragons' Den

Investment Pitch for PhysiCool

Introduction to PhysiCool

• Kay Russell introduces herself and her company, Physical Limited, seeking a £100,000 investment for 20% equity.

• The company was launched in 2007 at the London Marathon to gain exposure and feedback while starting sales.

Product Overview

• Kay explains that the product is a reusable cooling bandage designed to treat inflammation and bruising.

• The bandage gradually cools an injured area without causing shock, pulling heat away rather than driving cold in.

Demonstration of Effectiveness

• The bandage provides cooling relief for two to three hours; it can be reactivated with a spray when dried out.

• Peter Jones questions the uniqueness of the product, noting previous experiences with similar bandages.

Unique Selling Proposition

• Kay asserts that their coolant is unique and patented, which differentiates it from other products on the market.

• She demonstrates how the coolant alleviates discomfort from sunburn or blisters without causing irritation.

Financial Insights

• Kay shares her background in horse breeding and training, indicating her long-term commitment to her ventures.

• She reveals financial performance: a loss of £3,000 in 2007 but achieving £30,000 in sales by October of that year.

Revenue Streams and Market Focus

• Current turnover is projected at around £60,000 for the year; significant income comes from partnerships with distributors like OrthoCare in India.

• Initially targeting sports injuries, Kay notes a shift towards medical markets as demand grows.

Separate Business Ventures

• Kay mentions another product line called Equinice for horses under a separate company generating about £80,000 this year.

• Questions arise regarding why she has separated these businesses despite substantial revenues from both.

Investment Dynamics in Competing Businesses

Disappointment in Business Structure

• The speaker expresses disappointment over a profitable business selling similar products but is not seeking investment, indicating a disconnect between potential and current operations.

• Acknowledgment that the business relationship seems unfair, leading to the decision to withdraw from investment discussions.

Market Segmentation and Branding

• There’s agreement on the necessity of branding two businesses separately due to their distinct markets; consumers prefer not to associate horse products with personal care.

• An investor shows interest in both businesses but insists on combining them for an investment offer, requesting a 30% share.

Competitive Offers and Acceptance

• Deborah Meadon surprises everyone by offering investment in both companies, prompting other investors to reconsider their positions.

• One investor feels unable to compete with Meadon’s offer and opts out, acknowledging the strength of her proposal.

Final Decision and Partnership Formation

• The entrepreneur expresses gratitude towards Meadon’s offer multiple times, hinting at eagerness to accept it while also confirming withdrawal from other offers.

• Kay successfully secures an experienced investor despite giving away more equity than initially intended.

Innovative Stress Relief Business Proposal

Introduction of Kuchikuku Limited

• Dr. Gili Kuchi introduces her company seeking £100,000 for 20% shares, emphasizing her background in pharmaceuticals and stress relief solutions.

Current Operations and Expansion Plans

• The business currently operates concessions within upscale hair salons and plans expansion into additional branches while developing its product line.

Unique Product Offering

• The company utilizes Hawaiian kukui nut oil known for its benefits against skin conditions like eczema and allergies as part of its treatment offerings.

Financial Overview

• Dr. Kuchi reports a turnover of £180,000 with a net profit of £55,000; she clarifies that she does not take a salary currently as the company has no debts.

Skepticism Over Projections

• Peter Jones questions the credibility of financial figures presented by Dr. Kuchi regarding projected sales based on recent performance rather than historical data.

Gilly's Troubling Pitch

Confusion Over Financial Figures

• Gilly struggles to provide clear financial figures, leading to frustration from Theopophetus. He asks for straightforward answers regarding her company's turnover and profit.

• Gilly initially states a turnover of £50,000 but later corrects it to £55,000 for December 2006, which raises suspicions about the accuracy of her numbers.

• Theopophetus highlights the coincidence of multiple figures being the same (all at £55,000), suggesting a lack of understanding on Gilly's part regarding her business metrics.

Criticism from Investors

• Peter Jones expresses disbelief in Gilly's grasp of her business numbers and suggests she should admit her confusion rather than misrepresenting them. He indicates that this could jeopardize investment opportunities.

• Deborah Meadon is the first investor to withdraw after expressing dissatisfaction with Gilly’s presentation and clarity on financial matters. She feels that Gilly has not provided trustworthy information.

Further Investor Reactions

• Richard Farley points out that while Gilly claims a profit based on sales figures, there is inconsistency in how these numbers are presented across different timeframes (previous year vs forecast). This leads him to conclude she lacks essential knowledge for investment consideration.

• Peter Jones reiterates that despite initial interest in Gilly’s product presentation, her failure to clarify financial details has made her uninvestable in his eyes as well. He decides to withdraw from investing.

Last Chance with Duncan Bannatyne

• Duncan Bannatyne remains interested but questions whether Gilly truly understands her financial situation under pressure; he believes she does know but is confused by questioning tactics used by others.

• Despite some clarification attempts by Duncan regarding annualized profits based on recent performance, he ultimately concludes that while there may be potential, the business isn't currently investable due to its unclear financial standing.

Conclusion of Pitch Session

• After all investors except Duncan have withdrawn their offers, it becomes evident that Gilly leaves without securing any investment due to significant concerns over her understanding of key business metrics and projections for future profitability.

Introduction to RBR Active Limited

Overview of the Business and Personal Story

• Paul Westerman introduces himself as the managing director of RBR Active Limited, which focuses on a deep vein thrombosis prevention device called the RBR leg flow.

• He shares a personal story about suffering a massive bilateral pulmonary embolism just days before his wedding due to undiagnosed deep vein thrombosis (DVT).

• The product aims to combat DVT by significantly increasing blood flow while users are sedentary.

Product Demonstration and Market Potential

Exercises and Target Audience

• Paul demonstrates simple exercises using the RBI leg flow, emphasizing its effectiveness for those who travel or remain seated for long periods.

• Peter Jones relates personally to the issue, sharing his own experience with DVT after a long flight, highlighting the real-world relevance of Paul's product.

Market Size and Opportunities

• Paul discusses potential markets, noting that airlines like Qantas serve over 40 million passengers annually and that NHS admits millions of patients each year.

• He mentions ongoing discussions with Qantas' chief medical officer regarding onboarding their flights post-COVID.

Design Concerns and Financial Insights

Product Design Feedback

• Sarah Davies praises the product but raises concerns about its portability in her travel bag, suggesting design improvements for better convenience.

Financial Performance

• Paul reveals financial details: no trading in 2018 despite an investment of £30,000; subsequent investments totaled £60,000 with only £6,500 turnover reported by 2021.

• The retail price is set at £24.99 with production costs around £2.30 per unit; suggestions are made to lower retail prices for broader accessibility.

Challenges in Consumer Awareness

Understanding Market Needs

• Stephen Bartlett acknowledges Paul's transformation of personal hardship into purpose but points out challenges in marketing a product that consumers may not realize they need until it's too late.

Future Solutions through Technology

• Stephen suggests wearable technology could enhance awareness and encourage preventive measures against DVT.

Intellectual Property Considerations

Protection Against Copycats

• Deborah Meaden questions Paul's intellectual property protections; he confirms trademark registration but lacks patent protection for the design rights.

Investment Pitch Analysis

Concerns Over Patent and Market Viability

• The speaker highlights a significant risk regarding the product's lack of patent protection, noting that similar products already exist in the market, which diminishes its uniqueness.

• Sara Davies expresses skepticism about the investment potential due to the absence of a patent, indicating it greatly reduces the proposition's value for investors. She decides to withdraw from consideration.

• Stephen Bartlett acknowledges that while the product may help some individuals, he doubts its ability to generate substantial profits necessary for investor returns. He warns against further financial investment without clear market traction.

Investor Reactions and Insights

• Another investor shares disappointment over the lack of intellectual property (IP), stating that if there had been a patent, their conversation would have been different. They ultimately decide not to invest.

• The same investor reiterates their decision to withdraw due to concerns about IP issues affecting investment viability.

Exploration of Potential Investment

• Peter Jones exits discussions, leaving Paul with dwindling hopes for securing an investment as other investors express hesitance.

• Tukasulimu indicates willingness to explore potential investments despite existing uncertainties surrounding patents and market readiness.

Clinical Trials and Market Strategy

• Tukasulimu questions Paul about clinical trials conducted over three and a half years in New Zealand, emphasizing the importance of having trial documentation ready for review.

• Discussion shifts towards potential revenue streams such as partnerships with airlines or vending machines, suggesting innovative ways to monetize the product.

Final Offer and Outcome

• Tukasulimu makes an offer of £50,000 for 35% equity in exchange for exploring unknown aspects of the business further.

• Paul agrees to Tukasulimu’s terms enthusiastically, expressing hope that this partnership will help realize his business aspirations.

• Paul successfully secures funding and support from Tukasulimu, marking a pivotal moment in his entrepreneurial journey filled with mixed emotions.